L Galluzzi, L Senovilla, I Vitale, J Michels, I Martins, O Kepp, M Castedo, G Kroemer
2012/4
Oncogene
31
15
ページ
1869-1883
Nature Publishing Group
Platinum-based drugs, and in particular cis-diamminedichloroplatinum (II)(best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis. Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described. Here, we provide a systematic discussion of these mechanism by classifying them in …
Scholar の論文
L Galluzzi, L Senovilla, I Vitale, J Michels, I Martins… - Oncogene, 2012